4 Key Trends at the Country Manager Level in China
Multinational pharma companies have been setting up shop in China ever since Novartis launched its Chinese affiliate in 1987, with other pharma giants following in its footsteps soon after, eager…
Address: No.97,Lane 1518,Guangfulin Road,Songjiang District,Shanghai,201620,P.R.China
Tel: 86 2161 026 752
Web: http://www.hoborchem.com/
Shanghai Hobor Chemical Co., Ltd is a production-oriented enterprise dedicated to pharmaceutical intermediates and active pharmaceutical ingredients synthesis and process development,Hobor Chemical has been committed to expedite our customer’s R&D and manufacturing in a time and cost effective manner since 2010 the company started.We focuses on developing efficient process technology for intermediates,active ingredients.
Our R&D lab located in Hi-Tech Park of Shanghai,China,the facility located in Fengxin industrial area,Jiangxi Province,employees experienced chemistry and medicine R&D team and equipped with the state of the art instruments.to be able to complete the low temperature of -80 to 300 high temperature a variety of reactions.Our products are strictly controlled by the LC, NMR,MS ensure customer satisfaction with every batch of products. We have established very good relationship with many global customers since company started.
Custom Synthesis As a innovative research company and active high-tech building block supplier, we are eager to become your professional partner in the following fields:
1. Heterocyclic chemistry and it’s synthetic technology
2. APi’s structure and it’s process research3. Cost effective process for pharma intermediates4. Chiral chemicals realted to above region
We provide Explore new synthetic chemistry Synthesis of novel and/or know compounds Substantial experience in process development, scale up and commercialization Able to follow an entire project, from laboratory to pilot production
QA manager is always involved in working together with our marketing colleage to identify suitable supplier, ensure the quality of products, and control the risks in supply chain.
Multinational pharma companies have been setting up shop in China ever since Novartis launched its Chinese affiliate in 1987, with other pharma giants following in its footsteps soon after, eager…
Gaobo Zhou is Partner and co-leader of the Healthcare Practice in China and has been with McKinsey for over a decade, Gaobo discusses the changes occurring within the complex and…
“Mental health is currently a major problem in China, and will become an ever greater problem unless effective interventions are put in place.” Mental Health has Long Been a…
Pius Hornstein, Country Chair of Sanofi China appointed in March 2019, shares his initial impressions on the fast-changing Chinese market; his mandate to drive a transformation of the organization in…
HE Ming, founder and CEO of Sino-American (Suzhou) Pharmaceutical Services (SAPS), shares his commitment to bringing international quality standards to the Chinese pharma industry, the comprehensive portfolio of quality management,…
Dr Shuqian Jing, founder, Chairman and CEO of Gmax Biopharm, an innovative biotech company headquartered in Hangzhou, shares how his experiences at global biopharma companies like BMS and Amgen inspired…
Serial entrepreneur and Ronnsi CEO Yiming Yao discusses the inspiration behind the company’s formation, its unique specialization in ovine heparin, and his strategy to take the firm to the next…
China’s rapidly-growing biotech sector is increasingly hungry for preclinical drug candidates to commercialise in China, and Chinese companies are spending top dollar for cutting-edge technology from the US and UK.…
Dr Dafang Zhong, director of Shanghai Center for Drug Metabolism and Pharmacokinetics Research at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, shares his professional career within the…
Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions…
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in…
See our Cookie Privacy Policy Here
